XML 31 R52.htm IDEA: XBRL DOCUMENT v2.4.0.8
Intermolecular (Details) (USD $)
3 Months Ended 12 Months Ended 3 Months Ended 12 Months Ended 12 Months Ended 3 Months Ended
Dec. 31, 2013
Sep. 30, 2013
Jun. 30, 2013
Mar. 31, 2013
Dec. 31, 2011
Sep. 30, 2011
Jun. 30, 2011
Mar. 31, 2011
Dec. 31, 2013
Dec. 31, 2012
Dec. 31, 2011
Nov. 18, 2011
Symyx Technologies, Inc.
Jul. 28, 2011
Symyx Technologies, Inc.
board_members
Nov. 15, 2011
Symyx Technologies, Inc.
Cost Method Investee
Jun. 30, 2013
Symyx Technologies, Inc.
Intermolecular Inc.
Dec. 31, 2011
Symyx Technologies, Inc.
Intermolecular Inc.
Dec. 31, 2013
Symyx Technologies, Inc.
Intermolecular Inc.
Nov. 18, 2011
Symyx Technologies, Inc.
Intermolecular Inc.
Dec. 31, 2013
Symyx Technologies, Inc.
Intermolecular Inc.
Notes Receivable
Dec. 31, 2011
Symyx Technologies, Inc.
Intermolecular Inc.
Cost Method Investee
Notes Receivable
Nov. 18, 2011
Symyx Technologies, Inc.
Intermolecular Inc.
Cost Method Investee
Notes Receivable
Jul. 28, 2011
Common Stock
Symyx Technologies, Inc.
Schedule of Cost-method Investments [Line Items]                                            
Intermolecular, Inc. stock held by Symyx Technologies, Inc.                                           3,968,204
Stock split conversion ratio                           0.5                
Intermolecular, Inc. board members appointed by Symyx Technologies, Inc.                         1                  
Gross proceeds from sale of IM shares                                         $ 67,000,000  
Reimbursement to Symex Technologies, Inc. for underwriting discount and commission payable related to sale of Intermolecular, Inc. stock, percentage                         50.00%                  
Shares of Intermolecular, Inc. stock sold by Symyx Technologies, Inc.                       3,968,204                    
Cost method investment                       $ 10.00                    
Aggregate proceeds from sale shares of IM stock                               39,700,000            
Sale of Intermolecular, Inc. stock, transaction costs                               1,400,000            
Net gain on sale of cost method investment         18,970,000 0 0 0 0 0 18,970,000         19,000,000            
Consulting costs related to Intermolecular, Inc.                               1,000,000            
IM Note                                         27,300,000  
Contractual term of promissory note receivable from Intermolecular, Inc.                                     24 months      
Promissory note receivable, interest rate                                   4.00%        
Minimum quarterly installments on promissory note receivable from Intermolecular, Inc.                                 500,000          
Promissory note receivable, fair value                                   26,000,000        
Net gain on sale of intellectual property $ 0 $ 0 $ 25,821,000 $ 74,000         $ 25,895,000 $ 0 $ 0       $ 25,900,000         $ 4,300,000    
Market interest rate for comparable instruments                                   6.89%